PRO Journal SA-CME activity for July-August, 2018 (Volume 8, Issue 2) summarizes recent evidence-based guidelines on palliation of stage III and IV non-small cell lung cancer.

IJROBP Journal SA-CME activity for July 1, 2018 (Volume 101, Issue 3) identifies the knowledge needed to treat patients with leukemia undergoing total body radiation as a component of stem cell transplantation.

IJROBP Journal SA-CME activity for June 1, 2018 (Volume 101, Issue 2) provides practitioners with the knowledge needed to discuss treatment options and expectations for treatment related sequelae to patients with meningioma.

PRO Journal SA-CME activity for May-June, 2018 (Volume 10, Issue 9) explores the clinical research leading to evidence-based guidelines for breast radiotherapy, particularly related to hypo-fractionation.

IJROBP Journal SA-CME activity for May 1, 2018 (Volume 101, Issue 1) informs readers of the incidence and likely mechanism of brainstem injury in the context of proton therapy.   Practical recommendations are made in modifying dose limits when using proton therapy to protect children wit

IJROBP Journal SA-CME activity for April 1, 2018 (Volume 100, Issue 5) provides practitioners with the  knowledge to make competent recommendations when they meet patients with borderline resectable pancreatic cancer.

IJROBP Journal SA-CME activity for March 15, 2018 (Volume 100, Issue 4) reviews the data available for treating rectal cancer in elderly patients, their ability to tolerate treatment and available options for achieving the correct balance between therapeutic opportunity and therapeutic b

IJROBP Journal SA-CME activity for March 1, 2018 (Volume 100, Issue 3) provides practitioners with clear guidelines for managing relapsed lymphomas and clear information about new targeted agents now in regular use.

PRO Journal SA-CME activity for March-April, 2018 (Volume 8, Issue 1) explores the use of field design and shielding techniques to reduce dose to gonad(s) when treating seminoma.

IJROBP Journal SA-CME activity for February 1, 2018 (Volume 100, Issue 2) provides practitioners with the knowledge needed to discuss treatment effects on non tumor liver (“normal” liver) in patients treated for hepatocellular cancer.